Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems.

The cellular uptake of antisense oligodeoxynucleotides (ODNs) may be enhanced by the use of carriers such as cationic liposomes or lipoplexes, but little is known about the intracellular fate and subcellular trafficking of these systems in target cells. In this study, we report on the cellular uptake and biodistribution of ODNs in the presence and absence of optimised self-assembled cationic lipoplexes using the C6 glioma cell line as an in vitro model. Biotin or radiolabelled 15-mer phosphorothioate (PS) ODNs were synthesised and their cellular uptake and subcellular biodistribution characterised in the presence and absence of an optimised cationic lipoplex delivery system using studies ranging from cellular association, cellular efflux and transmission electron microscopy (TEM). Ultrastructural studies clearly showed PS ODNs in the absence of liposomal delivery to be sequestered within endosomal and lysosomal vesicular bodies indicative of endocytic uptake. ODNs were also visible, to a lesser extent, in the nucleus and cytoplasm. By employing DOSPA (2'-(1",2"-dioleoyloxypropyldimethyl-ammonium bromide)-N-ethyl-6-amidospermine tetra trifluoroacetic acid) and DOPE (dioleoylphosphatidylethanolamine) complex in a 3 : 1 ratio, as a delivery system for ODNs at a optimal lipid/DNA charge ratio of 1 : 1, the level of ODN cellular association was significantly increased by approximately 10-12 fold with a concomitant change in subcellular distribution of PS ODN. TEM studies indicated enhanced penetration of ODN within the cytosol and the cell nucleus with reduced presence in vesicular compartments. Efflux studies confirmed that cationic lipoplexes promoted entry of ODNs into 'deeper' cellular compartments, consistent with endosomal release. Optimised cationic lipoplexes improved cellular delivery of ODNs by enhancing cell association, uptake and by favourably modulating the intracellular trafficking and distribution of ODNs into non-vesicular compartments including the cytosol and nucleus.

[1]  A. Gewirtz,et al.  Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. , 1995, The Journal of clinical investigation.

[2]  E. Kellenberger,et al.  Specimen preparation for electron microscopy using low temperature embedding resins , 1982, Journal of microscopy.

[3]  R. Juliano,et al.  Cellular uptake and intracellular fate of antisense oligonucleotides. , 1992, Trends in cell biology.

[4]  J. Philippot,et al.  A new cationic liposome encapsulating genetic material. A potential delivery system for polynucleotides. , 1995, European journal of biochemistry.

[5]  A. J. Hudson,et al.  Cellular uptake properties of a 2'-amino/2'-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA. , 1997, Antisense & nucleic acid drug development.

[6]  L. Huang,et al.  DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. , 1994, Biochimica et biophysica acta.

[7]  L. Neckers,et al.  Characterization of oligonucleotide transport into living cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[8]  F. Szoka,et al.  Rapid nuclear accumulation of injected oligodeoxyribonucleotides. , 1990, The New biologist.

[9]  S. Akhtar,et al.  Antisense technology: selection and delivery of optimally acting antisense oligonucleotides. , 1998, Journal of drug targeting.

[10]  R. Eritja,et al.  Digoxigenin-labeled phosphorothioate oligonucleotides: a new tool for the study of cellular uptake. , 1995, Antisense research and development.

[11]  L. Papucci,et al.  Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids. , 1994, Anti-cancer drug design.

[12]  G. Sczakiel,et al.  In vitro and in vivo action of antisense RNA , 1996, Molecular biotechnology.

[13]  A. Periasamy,et al.  Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. , 1991, Nucleic acids research.

[14]  R. Epand,et al.  Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity. , 1992, Biochimica et biophysica acta.

[15]  S. Agrawal,et al.  In vivo studies with antisense oligonucleotides. , 1997, Trends in pharmacological sciences.

[16]  R. Kole,et al.  Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. , 1991, Life sciences.

[17]  C. Bennett,et al.  Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. , 1992, Molecular pharmacology.

[18]  J. Legendre,et al.  Gene transfer mediated by cationic lipids: lack of a correlation between lipid mixing and transfection. , 1997, Biochimica et biophysica acta.

[19]  Zabner,et al.  Cationic lipids used in gene transfer. , 1997, Advanced drug delivery reviews.

[20]  R. Wagner.  Gene inhibition using antisense oligodeoxynucleotides , 1994, Nature.

[21]  K. Jayaraman,et al.  Novel Polyaminolipids Enhance the Cellular Uptake of Oligonucleotides (*) , 1995, The Journal of Biological Chemistry.

[22]  C. Stein,et al.  Patterns of intracellular compartmentalization, trafficking and acidification of 5'-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. , 1994, Nucleic acids research.